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The optimal management of patients with asymptomatic carotid stenosis (ACS) is the subject of 
extensive debate. According to the 2017 European Society for Vascular Surgery guidelines, carotid 
endarterectomy should (Class IIa; Level of Evidence: B) or carotid artery stenting may be considered 
(Class IIb; Level of Evidence: B) in the presence of one or more clinical/imaging characteristics that 
may be associated with an increased risk of late ipsilateral stroke (e.g., silent embolic infarcts on 
brain computed tomography/magnetic resonance imaging, progression in the severity of ACS, a 
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Introduction
The optimal management of patients with asymptomatic carot-
id stenosis (ACS) is a controversial and much debated issue. Ac-
cording to the 2020 Heart Disease and Stroke Statistics, each 
year around 800,000 Americans experience a new or recurrent 
stroke.1 Of these, about 600,000 are first strokes, while the rest 
are recurrent episodes.1 Projections show that by 2030, an addi-
tional 3.4 million United States adults will have suffered a 
stroke, representing a 20.5% increase in the prevalence from 
2012.1 
The global prevalence of ischemic stroke in 2017 was 82.4 
million; that is, a 16.1% increase from 2007 to 2017 and a 
10.1% increase from 1990 to 2017.1 Furthermore, a total of 2.7 
million individuals died globally of ischemic stroke in 2017.1 In 
Europe, there are approximately 1.4 million strokes/year caus-
ing about 1.1 million deaths annually.2 Around 10% to 15% of 
those strokes occur as a result of thromboembolism from a pre-
viously asymptomatic significant carotid stenosis.2,3 
Medical treatment has improved considerably in the last 10 
to 15 years.4 It was thus supported that the annual risk of stroke 
while on current best medical treatment (BMT) alone may be 
declining compared with the randomized controlled trials (RCTs) 
performed 20 to 30 years ago.2 Consequently, it was proposed 
that there is a need to develop clinical/imaging algorithms for 
identifying a smaller, but higher-risk for stroke cohort in whom 
carotid endarterectomy (CEA)/carotid artery stenting (CAS) 
might be targeted.2,5 The 2017 European Society for Vascular 
Surgery (ESVS) guidelines for the management of patients with 
carotid artery stenosis recommended that in “average surgical 
risk” patients with a 60% to 99% ACS, CEA should (Class IIa; 
Level of Evidence: B) or CAS may be considered (Class IIb; Level 
of Evidence: B) in the presence of one or more clinical/imaging 
characteristics that may be associated with an increased risk 
of late ipsilateral stroke, provided documented perioperative 
stroke/death rates are <3% and patient life expectancy is >5 
years.2 These clinical/imaging characteristics included silent 
embolic infarcts on brain computed tomography (CT)/magnetic 
resonance imaging (MRI), progression in the severity of ACS, 
a history of contralateral transient ischemic attack/stroke, mi-
croemboli detection on transcranial Doppler, the presence of 
intraplaque hemorrhage or plaque ulceration on MRI, reduced 
cerebrovascular reserve, a large plaque area (>40 mm2) on ul-
trasound longitudinal images and plaque echolucency as shown 
by a low gray scale median (<30) and presence of a large (>8 
mm2) juxtaluminal hypoechoic area after image normalization 
of Duplex ultrasound images.2,5-7
Besides these clinical/imaging characteristics, there are ad-
ditional individual, ethnic/racial, cultural or social factors that 
should probably be evaluated in the decision process regarding 
the optimal management of these patients. The current position 
statement considers the evidence why the optimal management 
of patients with ACS may occasionally need to be individual-
ized.
Individual characteristics to consider
Some factors/characteristics that may prompt physicians to 
consider individualization of the management of ACS in specific 
patients include.
Individual patient needs/patient choice
Not all patients have the same lifestyle and social/cultural 
background. Some patients are more active, others live more 
sedentary lives. The management of patients with different life-
styles should be tailored to their individual needs. In addition, 
patients have different characters and attitudes towards their 
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history of contralateral transient ischemic attack/stroke, microemboli detection on transcranial 
Doppler, etc.), provided documented perioperative stroke/death rates are <3% and the patient’s life 
expectancy is >5 years. Besides these clinical/imaging characteristics, there are additional 
individual, ethnic/racial or social factors that should probably be evaluated in the decision process 
regarding the optimal management of these patients, such as individual patient needs/patient 
choice, patient compliance with best medical treatment, patient sex, culture, race/ethnicity, age 
and comorbidities, as well as improvements in imaging/operative techniques/outcomes. The present 
multispecialty position paper will present the rationale why the management of patients with ACS 
may need to be individualized.
Keywords Endarterectomy, carotid; Carotid stenosis; Stroke; Ischemic attack, transient; Life expec-
tancy; Patient preference
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portant parameters.8 For some patients it may be quite stressful 
knowing that they have a high-grade ACS, which may lead to a 
stroke. In contrast, others may not wish to undergo a surgical 
procedure.8 Such individual factors, surroundings and attitudes 
should be taken into account when discussing the management 
of ACS with each patient. Patients have the right to choose if 
they want to undergo a procedure and accept the perioperative 
risk associated with CEA/CAS, or instead be managed by BMT 
alone. 
Traditional models where all treatment decisions are made by 
the health professionals are no longer desired by patients and 
their families.9 Patients want to be active participants in deci-
sion-making regarding their health and treatment choices.9 A 
survey from the UK a few years ago regarding the management 
of a unilateral 70% ACS revealed that 48% of the study par-
ticipants would opt for BMT alone whereas 52% preferred an 
intervention (30% CEA; 22% CAS).10 The most common reasons 
for choosing BMT over an intervention were avoidance of sur-
gery and the risk of periprocedural stroke/death. 
A subgroup analysis by gender demonstrated that 43% of 
men and 60% of women opted for BMT.10 Another 35% of men 
and 20% of women selected CEA, while CAS was preferred by 
22% of men and 20% of women.10 A subgroup analysis by age 
revealed that BMT was preferred by 39% of patients aged <70 
years versus 55% for those ≥70 years, whereas CEA by 35% (<70 
years) versus 27% (≥70 years) and CAS by 26% (<70 years) ver-
sus 18% (≥70 years), respectively. Patients with a first-degree 
relative who had suffered a stroke were equally likely to choose 
an intervention compared with individuals who did not have 
a similar history (52% vs. 53%, respectively).10 Furthermore, a 
larger proportion of patients who had suffered a contralateral 
event chose BMT compared with those who had never had a 
stroke or transient ischemic attack (64% vs. 47%). Active smok-
ers expressed a modest preference for CEA (8/21, 38%) over 
BMT (7/21, 33%) or CAS (6/21, 29%), while ex- and non-smok-
ers preferred BMT (42/81, 52%) over CEA (23/81, 28%) or CAS 
(16/81, 20%).10 Overall, the group most likely to opt for an open/
endovascular intervention was male smokers under 70 years of 
age.10 
Avoidance of surgery and the associated periprocedural risk 
may be valid reasons to choose BMT over CEA/CAS.10 On the 
other hand, the lower stroke/death rates associated with CEA 
compared with CAS may play a pivotal role for some patients 
when selecting an intervention. By contrast, others opt for the 
less invasive CAS over CEA, placing more emphasis on the scar 
size, a previous positive experience with arterial stenting else-
where (e.g., in the lower limb arteries) and the lower cranial 
nerve injury rates.10 Thus, individual ACS patients may opt for 
different treatment options using a variety of criteria.
Individual patient culture/ethnicity/race
The decision to undergo CEA may vary by ethnicity/race. Black 
patients may have higher aversion scores to CEA compared with 
white individuals.11 One of the reasons that might influence this 
decision to avoid CEA may be the fact that CEA does not relieve 
pain or prolong life, but is performed to reduce the risk of future 
stroke.11 According to the authors,11 the “risk of future stroke” 
may be a difficult concept to explain to some individuals. 
A large study (n=890,680 patients undergoing CEA/CAS; 
92.1% for ACS) identified ethnic/racial and financial disparities 
in the decision to be offered CEA for ACS.12 Compared with 
white ACS patients, black (odds ratio [OR], 0.72; 95% confi-
dence interval [CI], 0.69 to 0.75; P<0.0001), Hispanic (OR, 0.79; 
95% CI, 0.76 to 0.82; P<0.0001), and Asian patients (OR, 0.81; 
95% CI, 0.76 to 0.82; P<0.0001) were less likely to be offered 
a carotid revascularization procedure for ACS.12 When adjusted 
for age (<65 years vs. ≥65 years), black (OR, 0.73; 95% CI, 0.69 
to 0.78; P<0.0001), and Hispanic ACS patients (OR, 0.79; 95% 
CI, 0.74 to 0.85; P<0.0001) were less likely to be offered a re-
vascularization procedure compared with white ACS patients 
<65 years, whereas Asian patients did not differ significantly 
(OR, 0.91; 95% CI, 0.78 to 1.06; P>0.05). In contrast, for those 
≥65 years, black (OR, 0.74; 95% CI, 0.71 to 0.78; P<0.0001), 
Hispanic (OR, 0.79; 95% CI, 0.76 to 0.83; P<0.0001), and Asian 
patients (OR, 0.77; 95% CI, 0.70 to 0.84; P<0.0001) were all 
less likely to be offered a carotid revascularization procedure 
for ACS compared with white individuals. Finally, Medicaid (OR, 
0.60; 95% CI, 0.58 to 0.64; P<0.0001), private insurance (OR, 
0.78; 95% CI, 0.77 to 0.79; P<0.0001), and self-pay patients 
(OR, 0.37; 95% CI, 0.28 to 0.46; P<0.0001) were less likely to be 
offered CEA for ACS compared with Medicare individuals.12
Minority patients and individuals of lower socioeconomic sta-
tus have generally less access to medical care for the treatment 
of vascular risk factors. An analysis of data from the National 
Health and Nutrition Examination Surveys demonstrated that 
Hispanic and black patients were significantly less likely to have 
adequate control of hypertension and hypercholesterolemia 
compared with white patients.13 Another study demonstrated 
that black patients were less likely to be aware of and con-
trolled/treated for dyslipidemia compared with white patients.14 
Finally, a report from the Center for Disease Control and Pre-
vention showed that black patients not only had higher rates of 
hypertension compared with white patients, but they were also 
less likely to have blood pressure control.15
Besides the factors associated with a patient’s likelihood 
to be offered CEA or his/her decision to undergo CEA (which 
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may vary according to ethnic criteria/beliefs), another param-
eter which may affect individual decision-making is that CEA 
outcomes may vary by ethnicity/race. In the New York Carotid 
Artery Surgery Study (n=9,308 CEA procedures), individuals of 
Hispanic-Latino ethnicity undergoing CEA had considerably 
higher death and stroke rates compared with non-Hispanic 
black or non-Hispanic white patients (9.50% vs. 6.93% vs. 
3.80%, respectively; P<0.0001).16 Possible explanations for these 
disparities in outcomes according to patient ethnicity include 
increased comorbidities preoperatively, poor patient selection, 
confounding by socioeconomic status and other non-medical 
factors including increased proportion of non-white patients 
offered CEA at low-volume institutions by less experienced 
surgeons.16-20 Chaturvedi et al.20 demonstrated that black ACS 
patients receiving CEA in two urban hospitals tended to have 
higher stroke or myocardial infarction (MI) rates compared 
with white individuals (15.4% vs. 5.6%, P=0.065). In black pa-
tients who received surgery in the hospital with the lowest CEA 
volume, stroke or MI rates were significantly higher (20.5%, 
P<0.05) compared with white patients.20 The reasons for these 
unfavorable outcomes after CEA in black ACS patients included 
a higher prevalence of vascular risk factors (e.g., hypertension, 
diabetes, and smoking) and more women treated with CEA.20 
Consequently, the association between individual ethnic pa-
rameters with CEA outcomes may affect the type of treatment 
selected by patients or offered by physicians.
Patient age/comorbidities
As active and well-informed participants by health profession-
als, patients can make their own decision about whether to un-
dergo a prophylactic CEA. Age and comorbidities may play a key 
role in their decision-making (Table 1).16,21-27 According to na-
tional statistics, the 5-year mortality of individuals aged 80 to 
85 years is nearly 30.0% and it is higher in males than in fe-
males (40.6% vs. 23.4%, respectively; P<0.0001).21 Due to the 
high non-stroke-related mortality in this age group (e.g., due to 
cancer, respiratory causes, etc.), the net benefit of a prophylac-
tic CEA in such elderly patients is debatable.21,28 Furthermore, 
octogenarians and nonagenarians have been excluded from 
past RCTs; consequently, the number needed to treat to prevent 
one stroke in elderly ACS patients is unknown.28,29 The need to 
be cautious when offering a carotid intervention to elderly pa-
tients was underlined by some authors.22,23 Appropriate and rig-
orous patient selection for a carotid intervention is mandatory, 
especially in such a fragile population.24
Patients with multiple comorbidities have a high risk not 
only of surgical/periprocedural complications, but also of future 
stroke. A large study collected data from the National Surgi-
cal Quality Improvement Program (NSQIP) about preoperative 
risk factors for all patients undergoing CEA from 2005 to 2011 
(n=44,832; 27,136 ACS patients).30 A frailty Risk Analysis Index 
(RAI) score was developed using various comorbidities (e.g., ma-
lignant disease, congestive heart failure, shortness of breath at 
rest, renal insufficiency, etc.) and social parameters (e.g., func-
tional status, type of residency [home, assisted living, nursing 
home], etc).30 A linear correlation was demonstrated in ACS pa-
tients undergoing CEA between increasing frailty RAI score with 
perioperative risk of stroke. Perioperative stroke/death rates in-
creased with increasing frailty RAI score, at some point reaching 
and exceeding the perioperative stroke/death threshold of 3%.30 
In another more recent (2005 to 2012) analysis of the NSQIP 
data, frailty was strongly associated with morbidity and mor-
tality among patients undergoing CEA, but not CAS.31 Among 
37,875 patients undergoing a carotid intervention, frailty was 
an independent predictor of complications (23.5% vs. 7.2%, 
respectively; P<0.001), mortality (5.2% vs. 1.1%, respectively; 
P=0.02), failure to rescue (12.1% vs. 4.7%, respectively; P=0.02), 
and 30-day readmissions (14.9% vs. 3.7%, respectively; P=0.03) 
compared with non-frail patients. Consequently, the potential 
benefits of offering an intervention (CEA/CAS) plus BMT versus 
BMT alone in elderly ACS patients must be counterbalanced 
against the potential risks associated with each option.
The value of informed consent is crucial. Patients should not 
be provided data from obsolete trials such as the Asymptomatic 
Carotid Atherosclerosis Study (ACAS),32 but instead should be 
counseled with the best possible information on outcomes with 
current BMT and surgical results. The results of an objective 
assessment of comorbidities by the treating physician (including 
patient frailty and life-expectancy) should be presented to the 
patient.9 They need to understand the uncertainty, risks and 
benefits of the management of ACS.9 Younger ACS patients 
with a longer life expectancy may prefer to have a prophylactic 
CEA, while older ACS patients may choose to avoid CEA/CAS.10 
In an analysis of the Statutory German Quality Assurance 
Database on all CEAs performed between 2009 and 2014 
(n=142,074; 85,738 for ACS), there was a strong association 
between in-hospital stroke/death rates with age.25 Age was as-
sociated with a higher risk of any in-hospital stroke/death (rel-
ative risk [RR] per 10-year increase, 1.19; 95% CI, 1.14 to 1.24; 
P<0.01) and a higher risk of death alone (RR, 1.68; 95% CI, 1.54 
to 1.84; P<0.01) in CEA patients. Age was also associated with 
a higher risk of stroke alone (RR, 1.05; 95% CI, 1.00 to 1.11; 
P<0.05), but this relationship was weaker.25
A study presenting the outcomes after 22,516 CAS proce-
dures (10,677 on symptomatic [47.4%] and 11,839 on ACS 
patients [52.6%]) revealed an interesting finding.33 ACS patients 
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offered CAS had periprocedural death, stroke and MI rates of 
1.0% (95% CI, 0.9 to 1.2), 2.3% (95% CI, 2.1 to 2.6), and 2.2% 
(95% CI, 2.0 to 2.5), respectively. Nevertheless, mortality rates 
during a mean follow-up time of 2 years for ACS patients were 
as high as 27.7% (95% CI, 26.4 to 28.9). For ACS patients aged 
≥80 years in particular (n=7,255 patients), a staggering mean 
2-year mortality of 41.5% (95% CI, 39.7 to 43.3) was reported.33 
Therefore, almost half of those ACS patients aged ≥80 years 
did not live long enough to obtain benefit from CEA in terms of 
stroke prevention.33 Similar results were reported in a more re-
cent single-center study discussing the outcomes of CEA in ACS 
nonagenarians.26 Based on the reported median postoperative 
survival of 29 months in their group of ACS nonagenarians, the 
authors advised that the enthusiasm for offering CEA to elderly 
ACS individuals should be tempered by the low survival rates.26 
This finding raises some serious concerns about the appropri-
ateness of offering carotid revascularization procedures to very 
elderly ACS patients. 
Patient sex
A previous analysis of combined results from ACAS11 and the 
Asymptomatic Carotid Surgery Trial (ACST)29 revealed that as-
ymptomatic men had a 51% RR reduction with CEA, whereas 
there was no clear benefit in women.34 Women with ACS tend 
to be older and their perioperative outcomes are worse.34 Elderly 
ACS women in particular have high mortality rates due to isch-
emic stroke (up to 40.0% at 5 years), which prevents a net ben-
efit from carotid revascularization.21 
Consequently, not only are older women at higher perioper-
ative stroke/death risk after CEA, but they are also more likely 
to experience more severe strokes and higher stroke disability. 
According to the 2020 United States Heart Disease and Stroke 
Statistics, each year approximately 55,000 more females than 
males suffer a stroke.1 Sex-specific stroke rates in some areas 
have declined significantly since 1993 for males, but not for fe-
males.35 This trend was seen for all-strokes and ischemic strokes, 
but not for hemorrhagic strokes.35
In addition, studies evaluating carotid plaques in women who 
have undergone CEA demonstrated more smooth muscle cells 
and a smaller degree of macrophage infiltration, suggesting a 
more stable phenotype.36 Clinicians also need to consider com-
peting risks of stroke. Elderly women, in particular, are more 
likely to have an ischemic stroke due to atrial fibrillation rather 
than ACS.37
An in vivo 3.0-T MRI study of carotid plaque features at-
tempted to explain the sex differences indicative of higher-risk 
Table 1. Studies reporting outcomes of carotid revascularization procedures in elderly ACS patients
Study Study aim/study design Results
Studies comparing different age groups
Halm et al.16 
  (2009)
Analysis of the results of 9,308 CEAs by age (<70 years: 2,152 
   CEAs; 70–79 years: 4,958 CEAs; ≥80 years: 2,198 CEAs)
Ipsilateral stroke/death rates (≥80 vs. 70–79 years): 
  4.82% vs. 3.73%; P<0.02
Rajamani et al.22 
  (2013)
Comparison of outcomes stratified by age (<75 vs. 75 to <80 vs. 
    80 to <85 vs. >85 years) among symptomatic (n=1,376) and 
asymptomatic (n=2,773) patients undergoing CEA
Overall mortality for patients <75 vs. >85 years: 
  0.1% vs. 1.7%; P=0.002
In-hospital death/stroke/MI for patients <75 vs. >85 years: 
  2.2% vs. 5.6%; P=0.003
Schmid et al.25 
  (2017)
Analysis of 142,074 CEAs (85,738 for ACS; 56,336 for symptomatic 
    carotid stenosis) from the Statutory German Quality Assurance 
Database between 2009–2014
Crude risk of any in-hospital stroke/death for ACS patients 
   aged <65, 65–69, 70–74, 75–79, and ≥80 years:  
1.0% vs. 1.3% vs. 1.3% vs. 1.5% vs. 1.9%, respectively 
(P<0.001 for trend)
Studies reporting outcomes in the elderly
Rinckenbach et al.27 
  (2007)
Evaluation of outcomes after CEA in 57 ACS patients 
  ≥80 years old
Perioperative ipsilateral stroke/death rate: 8.8%
Kaplan-Meier 5-year survival: 52%
De Rango et al.21 
  (2012)
Assessment of the clinical relevance of carotid revascularization 
   procedures in patients ≥80 years old (n=348 procedures in 323 
patients; 179 ACS patients)
All-cause 5-year mortality: 65.4%
All-cause 5-year mortality in ACS patients: 67.8%
Salomon du Mont et al.24 
  (2014)
Overview of the results of 132 CEAs in 118 patients ≥80 years 
  (50 CEAs on symptomatic; 82 CEAs on ACS patients)
Ipsilateral stroke/death rate for ACS patients: 4.88%
Wach et al.23 
  (2015)
Evaluation of CAS safety and efficacy in patients aged ≥90 years 
   (n=21 CAS procedures in 20 patients; 11 symptomatic; 9 ACS 
patients [10 CAS procedures])
Perioperative stroke rate for ACS patients: 10%
50% of ACS patients were alive at 47 months
Hobbs et al.26 
  (2020)
Analysis of CEA outcomes offered to 33 ACS patients ≥90 years 30-day mortality rate: 6.1%
Median survival: 29.4 months
ACS, asymptomatic carotid stenosis; CEA, carotid endarterectomy; MI, myocardial infarction; CAS, carotid artery stenting.
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plaques in males.38 A total of 131 ACS individuals (67 males, 
64 females) were imaged with a 3.0-T whole-body scanner. By 
univariate linear regression analysis, male patients had a high-
er prevalence of thin/ruptured fibrous cap (48% vs. 17%, for 
males vs. females, respectively; OR, 4.41; 95% CI, 1.97 to 9.87; 
P<0.01), lipid-rich necrotic core (73% vs. 50%, respectively; 
OR, 2.72; 95% CI, 1.31 to 5.65; P=0.01) and a higher incidence 
of intra-plaque hemorrhage (33% vs. 17%, respectively; OR, 
2.36; 95% CI, 1.03 to 5.38; P=0.04) compared with females.38 In 
multivariate logistic regression analysis after adjusting for body 
mass index, hyperlipidemia, statin use, and angiographic steno-
sis on MRI, the adjusted OR remained virtually unchanged for 
the prevalence of thin/ruptured fibrous cap (adjusted OR, 4.41; 
95% CI, 1.97 to 9.87; P<0.01) and the presence of a lipid-rich 
necrotic core (adjusted OR, 3.66; 95% CI, 1.67 to 8.00; P=0.01). 
However, the prevalence of intraplaque hemorrhage was no 
longer significantly different (adjusted OR, 2.15; 95% CI, 0.93 
to 4.98; P=0.07).38 These results support a sex-specific approach 
for the invasive management of ACS.
An expert committee undersigning a multidisciplinary con-
sensus document recognized that the landmark RCTs have 
not been powered to assess outcomes specifically for women, 
because females were largely under-represented in all RCTs.39 A 
post hoc subgroup analysis of ACAS showed that the sex differ-
ences in CEA outcomes were mainly related to the higher oper-
ative stroke/death risk observed in women compared with men 
(3.6% vs. 1.7%, respectively), resulting in an inferior RR reduc-
tion in the overall benefit gained from CEA over time in females 
vs males compared with BMT alone (5-year relative RR, 17% vs. 
66%, for females vs. males, respectively).32 However, ACAS was 
performed between 1987 and 1993 and the trial did not have a 
pre-specified sex subgroup analysis, as was the case with ACST 
I.29 In ACST I,29 the 5-year benefit gained from CEA in women 
was half of that achieved in men (absolute RR, 4.08% vs. 8.21%, 
respectively). At 10 years, a benefit gained from CEA was only 
seen in women <75 years of age, but it was still inferior to that 
provided by CEA in asymptomatic men of similar age.40 A me-
ta-analysis of ACAS32 and ACST I29 data showed a significant 
benefit with surgery compared with BMT for ACS men (OR, 0.49; 
95% CI, 0.36 to 0.66), but not for women (OR, 0.96; 95% CI, 
0.63 to 1.45; pooled interaction P=0.01).41 A possible reason for 
the inferior results of CEA/CAS in women compared with men 
may be the fact that females with ACS often receive suboptimal 
medical care.42 
According to the recommendations of the committee par-
ticipating in the multidisciplinary consensus document, an 
equipoise between CAS/CEA and modern BMT for ACS is likely, 
but there is limited evidence to consider BMT alone as the best 
choice for the management of women with severe ACS (Grade 
2, Level of Evidence: B).42 A strong recommendation for CEA 
was provided for women with 60% to 99% ACS for reduction 
of long-term risk of stroke, provided the patient has a 5- to 10-
year life-expectancy and perioperative stroke/death rates are 
≤2.0% (Grade 1, Level of Evidence B). Furthermore, CAS for ACS 
females should mainly be offered within the context of RCTs 
including a medical arm with/without a CEA arm.42 It was con-
cluded that the overall benefit of carotid revascularization in 
stroke prevention for women with ACS is expected to be lower 
than for ACS men (Grade 2, Level of Evidence: B).42
Patient adherence with BMT
Up to 50% of vascular patients cannot quit smoking.43,44 Other 
patients may discontinue taking their drugs (e.g., statins) be-
cause of side-effects or intolerance45,46 and older patients may 
forget to take their medication. A possible pharmacological re-
sistance to clopidogrel or aspirin should also be taken under 
consideration.47 Due to drug resistance/discontinuation or lack 
of adherence, patients often end up receiving suboptimal BMT 
and, consequently, inadequate stroke prevention therapy. 
As a result of the rigorous surveillance by the investigators 
in RCTs, patients may be more adherent in RCTs than in clinical 
practice. Consequently, the results of RCTs may often underes-
timate or overestimate the benefit of a therapeutic approach.48 
This discrepancy in the results between RCTs and real-life ob-
servational studies/registries should be taken into account when 
dealing with individual patients. Patients with multiple risk fac-
tors may have a higher chance of progression of ACS and may 
therefore need to be considered for more aggressive treatment 
strategies, including CEA or CAS.
The outcomes of ACS patients managed with BMT alone 
and not offered CEA/CAS may be worse in everyday clinical 
practice compared with those reported in RCTs. A study from 
Boston, USA. addressed the natural history of patients with 
moderate (50% to 69%) ACS managed with BMT alone and 
not offered any intervention (n=794 patients; 900 carotid ar-
teries).49 Plaque progression occurred in 262 arteries. Of these, 
36 patients (13.7%) developed ipsilateral neurologic symptoms. 
Of the entire cohort, 90 patients (11.3%) developed ipsilateral 
ischemic symptoms despite receiving BMT; 58% of these were 
strokes. The 5-year freedom from symptoms was 88.4%±1.5%, 
while the 5-year actuarial survival for the entire cohort was 
81.9%±1.5%, with no advantage seen with BMT.49
In the Asymptomatic Carotid Stenosis and Risk of Stroke 
(ACSRS) study, 1,121 patients with 50% to 99% ACS receiving 
BMT underwent 6-monthly clinical assessment and carotid 
duplex ultrasound examinations for up to 8 years (mean fol-
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low-up, 4 years).50 ACS progression occurred in 222 patients 
(19.8%), while 130 first ipsilateral cerebral or retinal ischemic 
events (59 strokes) were recorded. For patients with 70% to 
99% ACS at baseline, the 8-year cumulative ipsilateral cerebral 
ischemic event rate was 12% in the absence and 21% in the 
presence of progression.50
A prospective, multicenter (n=36) study from China, the Re-
vascularization of Extracranial Carotid Artery Stenosis (RECAS) 
trial, demonstrated that ACS patients offered CEA in low-vol-
ume centers received suboptimal medical therapy preoperatively 
compared with high-volume centers, such as aspirin (73.0% vs. 
88.7%, respectively; P<0.001) and statins (25.6% vs. 34.9%, re-
spectively; P=0.008).51 A similar analysis from the United States 
using the Vascular Quality Initiative database and including pa-
tients undergoing CEA (n=71,283) and CAS (n=12,053) between 
2012 and 2017 demonstrated similar results.42 Around 10% to 
12% of patients did not receive an antiplatelet agent preoper-
atively, whereas approximately 20% did not receive a statin.42 
Finally, in a review of data from 3,382 patients admitted to a 
tertiary referral center with an ischemic stroke, 219 radiograph-
ically confirmed strokes adjudicated as carotid-mediated were 
studied.52 On admission, 50% were receiving antiplatelet ther-
apy and 55% were receiving lipid-lowering agents, most com-
monly statins (53%). A total of 35% individuals were receiving 
both an antiplatelet and lipid-lowering medication.52 Nearly 
half (96/219 patients; 43%) of the (previously asymptomatic) 
patients presented with an occluded carotid artery as the cul-
prit of their carotid stroke. Based on these results, the authors 
concluded that BMT alone is unlikely to provide sufficient stroke 
prevention for all patients with significant ACS.52 It was sug-
gested that the stroke risk of individual ACS patients should be 
stratified and the treatment should be tailored to each patient’s 
needs.53-55
Risk prediction tools/improvements in CEA out-
comes for ACS patients
Improvements in MRI/CT imaging techniques and technology 
nowadays make it possible to identify plaque features associat-
ed with increased stroke risk.56,57 Irregular plaque morphology 
and/or ulcerated plaque surface are associated with an in-
creased risk for future stroke. Similarly, the detection of in-
traplaque hemorrhage is an identifying feature of the vulnerable 
plaque and is strongly associated with cerebrovascular events.56 
Intraplaque hemorrhage may be a stronger predictor of stroke 
risk than clinical risk factors.57 Consequently, the use of MRI/CT 
imaging techniques may help to identify ACS patients at high 
risk for stroke who would benefit from a prophylactic carotid 
revascularization procedure.57
Besides the improvement in annual stroke rates with BMT 
alone,4 it should be considered that the periprocedural stroke 
rates associated with CEA for ACS patients have also improved. 
There are data from some centers where CEA was performed on 
Table 2. Predictors/prognostic factors associated with reduced long-term survival in asymptomatic carotid patients undergoing carotid endarterectomy
Study Age CAD COPD DM CKD CCO Smoking No statin Low Hb Other
Kragsterman et al.59 (2006) v v v Previous vascular surgery
Ballotta et al.60 (2007) v v v
Alcocer et al.61 (2013) v v v v v
Conrad et al.62 (2013) v v v v v Neck irradiation
Wallaert et al.63 (2013) v v v v v v v v
Gupta et al.64 (2013) v v v PAD, dependent functional 
  status
Wallaert et al.65 (2016) v v v v v v v v
Cooper et al.66 (2016) v v v v
DeMartino et al.67 (2017) v v v v v v v v Low BMI, prior vascular 
   surgery, ASA IV/V, no 
aspirin, prior contralateral 
CEA
Morales-Gisbert et al.68 (2017) v v v v
Carmo et al.69 (2018) v v v v v v
Keyhani et al.70 (2019) v v v v v v Low BMI, dementia 
Dasenbrock et al.71 (2019) v v v v ASA IV/V
CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; CKD, chronic kidney disease±dialysis; CCO, contralateral 
carotid occlusion; Hb, hemoglobin; PAD, peripheral arterial disease; BMI, body mass index; ASA, American Society for Anesthesiology; CEA, carotid endarterec-
tomy.
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ACS patients with death/stroke rates as low as 0.5%.58 There-
fore, the optimal management of some ACS patients (i.e., BMT 
alone vs. CEA+BMT) may also be guided by local surgical/medi-
cal expertise. 
An essential pre-requisite in order to offer a prophylactic 
carotid intervention to ACS patients is that those individuals 
should have a reasonable life-expectancy for maximum bene-
fit from the procedure.2 Carotid guidelines do not recommend 
offering an intervention to patients not expected to live long 
enough to benefit from the procedure.2 Various risk predic-
tion models have been developed in an attempt to identify 
prognostic factors associated with long-term survival in ACS 
patients undergoing CEA (Table 2).59-71 A number of negative 
prognostic factors have been identified, including old age (12 
studies),59,61-71 cardiac disease (12 studies),59-70 diabetes mellitus 
(11 studies),59-63,65,67-71 chronic obstructive pulmonary disease (10 
studies),61-70 chronic kidney disease with/without dialysis (six 
studies),61,63,65,69-71 statin non-use (five studies),62,63,65,67,69 contra-
lateral carotid occlusion (five studies),60,63,65,67,70 and smoking (four 
studies).63,65-67 The simultaneous presence of several of these 
conditions/criteria in ACS patients should prompt physicians to 
consider BMT instead of CEA/CAS for the management of these 
individuals. 
Conclusions
It has been supported that international guidelines are the “Holy 
Grail” in Medicine.72 Such guidelines ensure that the manage-
ment of patients is uniform and based on Level I Evidence gen-
erated by high-quality RCTs. Large, ongoing RCTs, such as the 
Carotid Revascularization Endarterectomy versus Stenting Trial 
(CREST)-273 and ACST-2,74 will generate high-quality data and 
evidence for clinical practice and should be vigorously support-
ed with enrollment of all eligible patients. However, due to local 
social/cultural population differences and resources in different 
parts of the world, a “one-size-fits-all” guideline policy may not 
be appropriate for all patients.72 Besides RCTs, future guidelines 
should also consider evidence from propensity-matched trials 
(preferably multi-center), audited registries and multi-registry 
analyses.72
Physicians should always seek to optimize patient adherence 
to BMT according to current guidelines because all-cause and 
cardiac mortality in ACS are very high.75 Nevertheless, some 
patients may require specific modifications based on individual 
lifestyle, personal traits, social and cultural characteristics, as 
well as emerging advances in the field (for example, specific 
vulnerable carotid plaque features like intraplaque hemorrhage, 
neovascularization, plaque volume and inflammation that can 
be detected with the newer imaging approaches).53,76 Deciding 
which is the right treatment for the right patient is crucial. 
Some patients deserve/require a more aggressive (or a more 
conservative) approach than others. Consequently, the manage-
ment of specific ACS patients may need to be individualized, 
with active patient participation in making health and treat-
ment choices.
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